Stockreport

Magenta Therapeutics Completes Dosing in Phase 1 MGTA-145 Trial, Demonstrating Rapid, Single-Day First Line Stem Cell Mobilization and Collection

Magenta Therapeutics, Inc.  (MGTA) 
Last magenta therapeutics, inc. earnings: 11/13 08:00 am Check Earnings Report
PDF – Updated data from the Phase 1 study in healthy subjects show that MGTA-145, in combination with plerixafor, met all primary and secondary endpoints –– Median of 4.1 mi [Read more]